use of antivirals R Confirmation/identification of at risk groups CDNA R Definition of minimum data set, as outlined in CDNA Surveillance Plan R Clinical management guidelines CDNA R Laboratory Case Definition PHLN R Guidance on PHLN The type of clinical specimen required Sample collection guidance Detection methodologies, such as culture, molecular methods such as Polymerase Chain Reaction, molecular characterization (typing and sub-typing methods and serology Quality assurance considerations R Laboratory Testing Protocols PHLN R Information regarding relevant isolates and sequencing PHLN data for test development R Point of care testing advice CDNA/PHLN R Advice that it is no longer necessary to test all cases PHLN/CDNA R Collation and analysis of jurisdictional data to show Department of emerging trends, as outlined in Surveillance Plan Health R Jurisdictional surveillance data, as outlined in S/T HD Surveillance Plan R Key messages communicated to Local Government, S/T HD NACCHO affiliates and jurisdictional industry peak NACCHO bodies through identified email contacts for pandemic. R Tailoring Infection Control Guidelines to pandemic CDNA + additional virus expertise R Advice regarding the need for additional action specific AHPPC on advice to institutional settings from CDNA, jurisdictions and GP Roundtable, Clinical Stakeholders Forum R Protocol outlining how people identified under exit AHPPC on advice screening should be managed. from CDNA PPM Telephone advice from the Department of Health Department of freecall Public Health Information Line (PHIL) 1800 Health 004 599. PHIL currently operates during business hours. During standby this may vary. PPM Health Alert Information lines with capacity to manage Department of inbound and outbound calls. (These can be set up within Health 2hours) PPM Access to information and advice from healthcare National Health Call professionals through a national call centre. Centre Network PPM Regular media conferences Department of Health
use of antivirals R Confirmation/identification of at risk groups CDNA R Definition of minimum data set, as outlined in Surveillance Plan CDNA R Clinical management guidelines CDNA R Laboratory Case Definition PHLN R Guidance on The type of clinical specimen required Sample collection guidance Detection methodologies, such as culture, molecular methods such as Polymerase Chain Reaction, molecular characterization (typing and sub-typing methods and serology Quality assurance considerations PHLN R Laboratory Testing Protocols PHLN R Information regarding relevant isolates and sequencing data for test development PHLN R Point of care testing advice CDNA/PHLN R Advice that it is no longer necessary to test all cases PHLN/CDNA R Collation and analysis of jurisdictional data to show emerging trends, as outlined in Surveillance Plan Department of Health R Jurisdictional surveillance data, as outlined in Surveillance Plan S/T HD R Key messages communicated to Local Government, NACCHO affiliates and jurisdictional industry peak bodies through identified email contacts for pandemic. S/T HD NACCHO R Tailoring Infection Control Guidelines to pandemic virus CDNA + additional expertise R Advice regarding the need for additional action specific to institutional settings AHPPC on advice from CDNA, jurisdictions and GP Roundtable, Clinical Stakeholders Forum R Protocol outlining how people identified under exit screening should be managed. AHPPC on advice from CDNA PPM Telephone advice from the Department of Health freecall Public Health Information Line (PHIL) 1800 004 599. PHIL currently operates during business hours. During standby this may vary. Department of Health PPM Health Alert Information lines with capacity to manage inbound and outbound calls. (These can be set up within 2hours) Department of Health PPM Access to information and advice from healthcare professionals through a national call centre. National Health Call Centre Network PPM Regular media conferences Department of Health
w-AHMPPI.docx